Roffman Miller Associates Inc. PA Sells 1,149 Shares of Danaher Co. (NYSE:DHR)

Roffman Miller Associates Inc. PA decreased its position in Danaher Co. (NYSE:DHR) by 2.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 44,301 shares of the conglomerate’s stock after selling 1,149 shares during the period. Roffman Miller Associates Inc. PA’s holdings in Danaher were worth $10,249,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. BKM Wealth Management LLC acquired a new position in shares of Danaher during the 4th quarter worth about $27,000. Wetzel Investment Advisors Inc. acquired a new position in shares of Danaher during the 4th quarter worth about $29,000. OFI Invest Asset Management acquired a new position in shares of Danaher during the 3rd quarter worth about $30,000. Rakuten Securities Inc. acquired a new position in shares of Danaher during the 4th quarter worth about $36,000. Finally, GHP Investment Advisors Inc. boosted its stake in shares of Danaher by 540.0% during the 3rd quarter. GHP Investment Advisors Inc. now owns 160 shares of the conglomerate’s stock worth $40,000 after buying an additional 135 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Ratings Changes

DHR has been the topic of a number of research analyst reports. KeyCorp upped their target price on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. TD Cowen increased their price target on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday. Raymond James increased their price target on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Royal Bank of Canada increased their price target on shares of Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Finally, HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and increased their price target for the company from $250.00 to $280.00 in a report on Wednesday, April 17th. Six equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $270.00.

Danaher Price Performance

Shares of NYSE DHR traded up $1.73 during trading hours on Friday, hitting $247.53. 1,714,820 shares of the stock were exchanged, compared to its average volume of 2,773,065. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.37 and a current ratio of 1.85. The company has a market cap of $183.34 billion, a PE ratio of 41.66, a price-to-earnings-growth ratio of 4.19 and a beta of 0.83. The company’s fifty day simple moving average is $248.94 and its two-hundred day simple moving average is $230.88. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $259.00.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. During the same quarter last year, the business posted $2.36 earnings per share. The company’s quarterly revenue was down 2.6% on a year-over-year basis. On average, sell-side analysts predict that Danaher Co. will post 7.64 EPS for the current year.

Danaher Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be given a $0.27 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. This is a positive change from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Insider Buying and Selling at Danaher

In related news, Director Teri List sold 3,289 shares of the business’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the sale, the director now owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, Director Teri List sold 3,289 shares of the business’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the sale, the director now owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the transaction, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The disclosure for this sale can be found here. Insiders have sold 84,132 shares of company stock worth $21,022,795 over the last quarter. Corporate insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.